331 related articles for article (PubMed ID: 8723469)
1. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
2. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
[TBL] [Abstract][Full Text] [Related]
4. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum.
Buffet PA; Garin YJ; Sulahian A; Nassar N; Derouin F
Ann Trop Med Parasitol; 1996 Jun; 90(3):295-302. PubMed ID: 8758143
[TBL] [Abstract][Full Text] [Related]
6. Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.
Reis LES; Fortes de Brito RC; Cardoso JMO; Mathias FAS; Aguiar Soares RDO; Carneiro CM; de Abreu Vieira PM; Ramos GS; Frézard FJG; Roatt BM; Reis AB
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827416
[TBL] [Abstract][Full Text] [Related]
7. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.
Ferreira FM; Castro RA; Batista MA; Rossi FM; Silveira-Lemos D; Frézard F; Moura SA; Rezende SA
Parasitol Res; 2014 Feb; 113(2):533-43. PubMed ID: 24292604
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
Minodier P; Retornaz K; Horelt A; Garnier JM
Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis.
Faraut-Gambarelli F; Piarroux R; Deniau M; Giusiano B; Marty P; Michel G; Faugère B; Dumon H
Antimicrob Agents Chemother; 1997 Apr; 41(4):827-30. PubMed ID: 9087498
[TBL] [Abstract][Full Text] [Related]
11. Comparing the therapeutic efficacy of different amphotericin B-carrying delivery systems against visceral leishmaniasis.
Mendonça DVC; Martins VT; Lage DP; Dias DS; Ribeiro PAF; Carvalho AMRS; Dias ALT; Miyazaki CK; Menezes-Souza D; Roatt BM; Tavares CAP; Barichello JM; Duarte MC; Coelho EAF
Exp Parasitol; 2018 Mar; 186():24-35. PubMed ID: 29448040
[TBL] [Abstract][Full Text] [Related]
12. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.
Golenser J; Frankenburg S; Ehrenfreund T; Domb AJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2209-14. PubMed ID: 10471566
[TBL] [Abstract][Full Text] [Related]
13. Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis.
Azevedo EG; Ribeiro RR; da Silva SM; Ferreira CS; de Souza LE; Ferreira AA; de Oliveira E Castro RA; Demicheli C; Rezende SA; Frézard F
Expert Opin Drug Deliv; 2014 Oct; 11(10):1551-60. PubMed ID: 24962630
[TBL] [Abstract][Full Text] [Related]
14. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
Banerjee A; De M; Ali N
J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
[TBL] [Abstract][Full Text] [Related]
15. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
16. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.
Sánchez-Brunete JA; Dea MA; Rama S; Bolás F; Alunda JM; Raposo R; Méndez MT; Torrado-Santiago S; Torrado JJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3246-52. PubMed ID: 15328080
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
18. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice.
Gershkovich P; Wasan EK; Sivak O; Li R; Zhu X; Werbovetz KA; Tidwell RR; Clement JG; Thornton SJ; Wasan KM
J Antimicrob Chemother; 2010 Mar; 65(3):535-7. PubMed ID: 20026611
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
20. Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.
Vélez ID; Colmenares LM; Muñoz CA
Rev Inst Med Trop Sao Paulo; 2009; 51(4):231-6. PubMed ID: 19739006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
